Acquired fluconazole resistance and genetic clustering in Diutina (Candida) catenulata from clinical samples.


Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 28 07 2022
revised: 26 09 2022
accepted: 28 09 2022
pubmed: 10 10 2022
medline: 8 2 2023
entrez: 9 10 2022
Statut: ppublish

Résumé

Diutina (Candida) catenulata is an ascomycetous yeast isolated from environmental sources and animals, occasionally infecting humans. The aim of this study is to shed light on the in vitro antifungal susceptibility and genetic diversity of this opportunistic yeast. Forty-five D. catenulata strains isolated from various sources (including human and environmental sources) and originating from nine countries were included. Species identification was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and confirmed via internal transcribed spacer ribosomal DNA barcoding. In vitro antifungal susceptibility was determined for seven systemic antifungals via the gradient strip method after 48 hours of incubation at 35°C using Etest® (Biomérieux) or Liofilchem® strips. Isolates exhibiting fluconazole minimal inhibitory concentrations (MICs) of ≥8 μg/mL were investigated for mutations in the ERG11 gene. A novel microsatellite genotyping scheme consisting of four markers was developed to assess genetic diversity. MIC ranges for amphotericin B, caspofungin, micafungin, isavuconazole, and posaconazole were 0.19-1 μg/mL, 0.094-0.5 μg/mL, 0.012-0.064 μg/mL, 0.003-0.047 μg/mL, and 0.006-0.032 μg/mL, respectively. By comparison, a broad range of MICs was noted for fluconazole (0.75 to >256 μg/mL) and voriconazole (0.012-0.38 mg/L), the higher values being observed among clinical strains. The Y132F amino acid substitution, associated with azole resistance in various Candida species (C. albicans, C. tropicalis, C. parapsilosis, and C. orthopsilosis), was the main substitution identified. Although microsatellite typing showed extensive genetic diversity, most strains with high fluconazole MICs clustered together, suggesting human-to-human transmission or a common source of contamination. The high rate of acquired fluconazole resistance among clinical isolates of D. catenulata is of concern. In this study, we highlight a link between the genetic diversity of D. catenulata and its antifungal resistance patterns, suggesting possible clonal transmission of resistant isolates.

Identifiants

pubmed: 36209989
pii: S1198-743X(22)00513-4
doi: 10.1016/j.cmi.2022.09.021
pii:
doi:

Substances chimiques

Fluconazole 8VZV102JFY
Antifungal Agents 0
Amphotericin B 7XU7A7DROE
Voriconazole JFU09I87TR
DNA, Intergenic 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

257.e7-257.e11

Informations de copyright

Copyright © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Auteurs

Céline Nourrisson (C)

Université Clermont Auvergne, Inserm, 3IHP, Centre Hospitalier Universitaire Clermont-Ferrand, Service de Parasitologie-Mycologie, Clermont-Ferrand, France; Université Clermont Auvergne/Inserm U1071, USC-INRAe 2018, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte, Clermont-Ferrand, France.

Maxime Moniot (M)

Université Clermont Auvergne, Inserm, 3IHP, Centre Hospitalier Universitaire Clermont-Ferrand, Service de Parasitologie-Mycologie, Clermont-Ferrand, France.

Rose-Anne Lavergne (RA)

Nantes Université, Centre Hospitalier Universitaire Nantes, Cibles et médicaments des infections et du cancer, IICiMed, UR 1155, Nantes, France.

Estelle Robert (E)

Nantes Université, Cibles et médicaments des infections et du cancer, IICiMed, UR 1155, Nantes, France.

Virginie Bonnin (V)

Université Clermont Auvergne/Inserm U1071, USC-INRAe 2018, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte, Clermont-Ferrand, France.

Ferry Hagen (F)

Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands; Institute for Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, the Netherlands; Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands.

Frédéric Grenouillet (F)

Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire Besançon, Besançon, France.

Claudia Cafarchia (C)

Dipartimento di Medicina Veterinaria, Università degli Studi 'Aldo Moro', Bari, Italy.

Geraldine Butler (G)

School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Belfield, Dublin, Ireland.

Sophie Cassaing (S)

Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire Toulouse, Toulouse, France.

Marcela Sabou (M)

Laboratoire de Parasitologie et de Mycologie Médicale, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Institut de Parasitologie et de Pathologie Tropicale, UR7292 Dynamique des interactions hôte pathogène, Fédération de Médecine Translationnelle, Université de Strasbourg, Strasbourg, France.

Patrice Le Pape (P)

Nantes Université, Centre Hospitalier Universitaire Nantes, Cibles et médicaments des infections et du cancer, IICiMed, UR 1155, Nantes, France.

Philippe Poirier (P)

Université Clermont Auvergne, Inserm, 3IHP, Centre Hospitalier Universitaire Clermont-Ferrand, Service de Parasitologie-Mycologie, Clermont-Ferrand, France; Université Clermont Auvergne/Inserm U1071, USC-INRAe 2018, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte, Clermont-Ferrand, France.

Florent Morio (F)

Nantes Université, Centre Hospitalier Universitaire Nantes, Cibles et médicaments des infections et du cancer, IICiMed, UR 1155, Nantes, France. Electronic address: florent.morio@chu-nantes.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH